<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">First, are patients with COVID-19 in other countries experiencing neurologic symptoms and do these symptoms affect the severity and course of the illness, specifically are they associated with increased respiratory failure or death? Documentation of neuropsychiatric comorbidities and drug treatment regimens is essential to aid ongoing discussions of drugâ€“drug interactions and pharmacodynamic effects. Vaccine research discoveries need to be implemented while keeping in mind possible adverse events as shown by our experiences with the swine flu [
 <xref ref-type="bibr" rid="CR14">14</xref>].
</p>
